Company News On-Call

Advanced Viral Research Corp.

May-10-2004 NEW STORY
ADVR Receives Second $3 Million Installment of Funding
Apr-20-2004
Advanced Viral Research Corp. Announces the Resignation of Its Chief Financial Officer
Apr-8-2004
ADVR Appoints Dr. Carol Epstein as Acting Medical Director
Mar-19-2004
ADVR Abstract Selected for Presentation at the American Society of Clinical Oncology's (ASCO) 40th Annual Meeting
Feb-25-2004
ADVR Granted a United States Patent for the Treatment of AIDS
Feb-20-2004
ADVR Presented Preclinical Data at the 1st ISC International Conference on Cancer Therapeutics in Florence
Feb-12-2004
ADVR Appoints Biotechnology Veteran Elma S. Hawkins As New Chief Executive Officer
Feb-4-2004
ADVR Secures $12 Million Financing
Jan-27-2004
ADVR to present at 1st ISC International Conference on Cancer Therapeutics - Molecular Targets, Pharmacology and Clinical Applications to be held in Florence, Italy
Jan-8-2004
ADVR Granted U.S. Patent for Treatment of Human Papillomavirus Infections
Dec-30-2003
ADVR Names Elma S. Hawkins to Board of Directors
Dec-30-2003
AVR118 Suppresses Progression of Disease in Animal Model of Multiple Sclerosis Developed at The Weizmann Institute of Science
Dec-3-2003
ADVR Reports AVR118 Inhibits Inflammatory Arthritis in Animal Model and in Rheumatoid Arthritis Patients in Human Clinical Trial
Nov-20-2003
ADVR's AVR118 Granted a Patent in China for the Treatment of AIDS
Nov-18-2003
Advanced Viral Research Corp. Announces Retention of James T. D'Olimpio, MD As 'Spokesperson at Large'
Nov-10-2003
ADVR Reports Positive Preliminary Results of AVR118 Clinical Trial in AIDS Patients Suffering from Body Wasting (Cachexia)
Aug-28-2003
ADVR Announces Search for New CEO and Appointment of Interim CEO
May-16-2003
ADVR Completes Private Placement Financing Transactions
Apr-11-2003
ADVR CEO Hirschman Comments on SARS on ABC World News Tonight
Mar-24-2003
ADVR Granted Therapeutic Composition Patent For Product R; U.S. Patent Awarded for Chemical Structure of Novel Peptide Nucleic Acid
Mar-18-2003
ADVR Begins Planning for Late Stage Phase II AIDS Clinical Trial In Israel
Feb-25-2003
ADVR Pursuing Options in NY Litigation; Continues to Press Florida Lawsuit
Jan-9-2003
ADVR Completes Private Placement Financing Transaction
Dec-17-2002
ADVR Files Stock Manipulation Suit in Florida
Dec-12-2002
Potential Use of ADVR's Product R to Treat AIDS Is Focus of A&U Magazine Article
Nov-14-2002
ADVR Begins Product R Israeli Clinical Trials; Quintiles Retained to Monitor/Audit Trials, Selikoff Center to Conduct Trials
Nov-8-2002
ADVR Announces Staff Reduction to Conserve Capital to Focus on Israeli Clinical Trials; Intent to Sell Bahamas Plant; Board Resignations
Oct-11-2002
ADVR's Product R Reverses Cancerous Properties of Human Promyelocytic Leukemia Cells in Laboratory Cultures
Sep-25-2002
Dr. Richard S. Kent Joins ADVR Board of Directors
Sep-18-2002
Dr. Sidney Pestka Joins ADVR Scientific Advisory Board
Sep-10-2002
ADVR Announces Completion of $3 Million Financing; Funds Enable Israeli Clinical Trials of Product R to Move Forward
Aug-20-2002
ADVR's Product R Subject of Published Study on Clinical Trial For Treatment of HIV/AIDS
Aug-13-2002
Paul R. Bishop Joins ADVR Board of Directors
Aug-13-2002
ADVR Announces $1.5 Million Investment By Member of Board and Member of Business Advisory Board
Aug-13-2002
ADVR's Product R Approved in Israel for Phase I Study In Patients with Solid Tumors
Aug-13-2002
ADVR's Product R Approved in Israel for Phase I Study in Leukemia and Lymphoma Patients
Aug-13-2002
Roy S. Walzer Joins Board of Directors of Advanced Viral Research Corp.
Aug-13-2002
ADVR's Product R Approved in Israel for Phase I/II Study In Patients Needing Salvage Therapy For AIDS
Aug-13-2002
ADVR Names Mayr Communications to Handle Public/Investor Relations; Firm Brings Extensive Pharmaceutical Industry Experience
Aug-13-2002
ADVR Names Eli Wilner Chairman of the Board
Aug-13-2002
ADVR's Dr. Hirschman Describes Large Potential Therapeutic Categories for Product R
Aug-13-2002
ADVR Is Assigned Ownership of Two U.S. Patents in Settlement of Litigation
Aug-13-2002
ADVR Begins Phase 2 of IND for Topical Treatment Of Genital Warts With Product R
Aug-13-2002
ADVR's Product R Granted Patent for Topical Use In Treatment of Skin Diseases, Eye Afflictions
Aug-13-2002
Dr. Howard Young - Leading Immunologist - Joins the Scientific Advisory Board Of Advanced Viral Research Corp.
Aug-13-2002
Advanced Viral Research Corp. Forms Scientific Advisory Board with Leaders in Oncology, Hematology, Women's Health Care
Aug-13-2002
Advanced Viral Research Corp. Submits Product R Topical Phase 1 Results to FDA


Issuers of news releases and not PR Newswire are solely responsible for the accuracy of the content.

More news from PR Newswire...
Copyright 1996-2002 PR Newswire Association LLC. All Rights Reserved.
A United Business Media company.